Siddhant U. Jain
Harvard University(US)Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Sarcoma Diagnosis and Treatment, Bone Tumor Diagnosis and Treatments, Epigenetics and DNA Methylation, Bone health and treatments, Glioma Diagnosis and Treatment
Most-Cited Works
- → Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape(2016)398 cited
- → H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis(2019)379 cited
- → PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism(2019)206 cited
- → Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas(2016)189 cited
- → H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2(2020)141 cited
- → Continued Activity of the Pioneer Factor Zelda Is Required to Drive Zygotic Genome Activation(2019)127 cited
- → Strategy for “Detoxification” of a Cancer-Derived Histone Mutant Based on Mapping Its Interaction with the Methyltransferase PRC2(2014)110 cited
- → Histone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase(2019)97 cited
- → S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3(2016)95 cited
- → Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression(2020)95 cited